AMINO ACID FORMULATIONS FOR PANCREATIC VIABILITY

• US 20200129465A1
• Filed: 04/24/2018
• Published: 04/30/2020
• Est. Priority Date: 04/25/2017
• Status: Active Grant

• Current Assignee: Almeda Labs LLC
• Original Assignee: Almeda Labs LLC
• Inventors: Tucker, Stacy, Nagaraj, Sushrutha
• Granted Patent: US 11,224,582 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/401 Proline; Derivatives thereof, e.g. captopril
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Amino acid formulations for pancreatic vitality. The formulations comprise a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine. Methods of enhancing pancreatic vitality, stabilizing blood glucose levels, and improving A1C levels in subjects in need thereof are also described.

Claims

1. An amino acid formulation for pancreatic vitality consisting essentially of a mixture of a plurality of amino acids, wherein the mixture comprises at least one amino acid selected from the group consisting of serine, glutamic acid, and/or carnitine.

2. The amino acid formulation of claim 1, wherein said mixture comprises at least serine and glutamic acid.

3. The amino acid formulation of claim 2, further comprising at least two amino acids selected from the group consisting of asparagine, carnitine, cysteine, isoleucine, lysine, and threonine.

4. The amino acid formulation of claim 1, wherein said mixture comprises at least carnitine.

5. The amino acid formulation of claim 4, further comprising at least two amino acids selected from the group consisting of arginine, glutamic acid, histidine, isoleucine, lysine, and serine.

6. The amino acid formulation of claim 1, wherein said mixture comprises at least 4 different amino acids blended together in unit dosage form.

7. The amino acid formulation of claim 6, wherein said unit dosage form comprises from about 400 to about 600 mg of said mixture.

8. The amino acid formulation of claim 7, wherein said unit dosage form is a pill, tablet, capsule, liquid solution, or gel cap.

9. The amino acid formulation of claim 1, wherein said mixture consists essentially of glutamic acid, isoleucine, lysine, serine, and threonine.

10. The amino acid formulation of claim 1, wherein said mixture consists essentially of carnitine, glutamic acid, isoleucine, lysine, and serine.

11. The amino acid formulation of claim 1, wherein said mixture consists essentially of asparagine, glutamic acid, serine, threonine and optionally cysteine.

12. The amino acid formulation of claim 1, wherein said mixture consists essentially of arginine, carnitine, histidine, isoleucine, and lysine.

13. The amino acid formulation of claim 1, wherein said mixture is substantially free of one or more amino acids selected from the group consisting of:

alanine, aspartic acid, glutamine, glycine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine, and valine.

14. The amino acid formulation of claim 1, wherein said mixture is substantially free of cysteine and asparagine.

15. The amino acid formulation of claim 1, wherein said mixture is substantially free of arginine and histidine.

16. A method of enhancing pancreatic islet cell viability, said method comprising contacting a pancreatic islet cell with a therapeutically effective amount of an amino acid formulation according to claim 1.

17. The method of claim 16, wherein said amino acid formulation is administered to a subject in need thereof for a therapeutically effective amount of time.

18. A method of decreasing or stabilizing blood glucose levels in a diabetic subject having elevated blood glucose levels, said method comprising administering a therapeutically effective amount of an amino acid formulation according to claim 1 to said subject for a therapeutically effective amount of time.

19. The method of claim 18, wherein said amino acid formulation is administered daily, twice per day as a unit dosage form.

20. A method of decreasing or stabilizing A1C levels in a diabetic subject, said method comprising administering a therapeutically effective amount of an amino acid formulation according to claim 1 to said subject for a therapeutically effective amount of time.